anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Bionomics · pitchdeck

Bionomics | Investor Presentation Deck | 38 slides

38 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Bionomics | Investor Presentation Deck | 38 slides

Bionomics · 2022-04
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 7 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides
— 0/2 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Traction 2 slides 100% 2/2 slides 100% 2/2 slides · 12 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides Why Now 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

38
every slide · same image gating as the playbook
01
Slide 1
Includes ticker symbols and date.front_matter
Open slide detail
02
other
Open slide detail
03
Uses a vertical timeline-style list to present company highlights.summarize
Open slide detailLoop · Golden Circle
04
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
Open slide detail
05
The slide uses a biological process diagram to explain allosteric modulation and a conceptual graph to illustrate how NAMs and PAMs restore normal activity.present_solution
Open slide detailBeat · Solution
06
Uses a biological mechanism diagram to contrast normal vs. disease states and the therapeutic intervention.present_solution
Open slide detailBeat · Solution
07
transition
Open slide detail
08
The chart uses a funnel-like visualization to show the narrowing of the target population from total prevalence to the specific opportunity for BNC210.size_opportunity
Open slide detailBeat · Market Size
09
The slide uses a bar chart to visualize efficacy data from a small-scale human study.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
10
Includes fMRI and behavioral task data from a 4-way crossover study.show_traction
Open slide detailBeat · TractionLoop · Quick Win Big Bet
11
The slide uses a flywheel diagram to illustrate the benefits of BNC210 and a comparison table to validate the competitive advantage.compare_peers
Open slide detail
12
Includes a pharmacokinetic chart showing concentration vs time for different doses.argue_timing
Open slide detailBeat · Why Now
13
The slide uses a process flow diagram to illustrate the clinical trial design.plan_implementation
Open slide detail
14
transition
Open slide detail
15
The slide uses a funnel-like visual to represent the patient population and market opportunity.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
16
The slide uses a before-after-bridge style structure to connect the problem (anxiety/PTSD) to the solution (BNC210) via experimental evidence.show_traction
Open slide detail
17
The slide uses a process flow diagram to show the evolution of the drug development program.plan_implementation
Open slide detail
18
The slide uses a combination of exposure-response modeling and pharmacokinetic data to validate the new formulation.present_solution
Open slide detail
19
The slide outlines a 12-week outpatient BID dosing period followed by a follow-up phase, with specific primary and secondary endpoints.plan_implementation
Open slide detail
20
The slide features a stylized icon of a human head containing a group of people and a microscope, overlaid with a network/process graphic.transition
Open slide detail
21
The slide highlights a specific partnership with Merck, detailing financial milestones and clinical progress, supported by bar charts showing efficacy in animalshow_traction
Open slide detail
22
The slide uses a newspaper graphic to frame the announcement as a significant news event.show_traction
Open slide detail
23
transition
Open slide detail
24
Includes images of ASX and Nasdaq listing displays.show_traction
Open slide detail
25
The slide uses a vertical timeline-like structure to present key strategic pillars.summarize
Open slide detail
26
appendix
Open slide detail
27
The slide uses a combination of headshots for the management team and a list format for the board of directors, accompanied by a grid of corporate logos.other
Open slide detail
28
appendix
Open slide detail
29
The central hub describes the drug mechanism, while the four quadrants detail specific symptom clusters and corresponding evidence.present_solution
Open slide detail
30
The table provides a comprehensive overview of clinical trial progress across multiple phases and indications.analyze_data
Open slide detail
31
The slide uses a combination of a line chart showing dose-response reduction and a process flow diagram to explain the mechanism of action.present_solution
Open slide detail
32
The slide uses a structured table layout to define the clinical trial parameters.present_framework
Open slide detail
33
The slide uses a mix of bullet points and a callout box for the 'reasons' section.summarize
Open slide detail
34
The slide features a stylized illustration of neurons, reinforcing the CNS (Central Nervous System) theme.transition
Open slide detail
35
The chart shows reversal of PCP-induced cognitive deficits in mice, with BL-76 showing dose-dependent efficacy.show_traction
Open slide detail
36
The slide uses a process-flow style layout to connect genetic rationale to compound development and preclinical results.present_solution
Open slide detail
37
appendix
Open slide detail
38
The slide details a specific business development milestone involving a licensing deal and potential revenue streams.show_traction
Open slide detail